Preparation and in vitro evaluation of anti-VCAM-1-Fab′-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib

References

• Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191–203
   PubMed Web of Science ®Google Scholar
• Bloemen PG, Henricks PA, van Bloois L, van den Tweel MC, Bloem AC, Nijkamp FP, Crommelin DJ, Storm G. Adhesion molecules: A new target for immunoliposome-mediated drug delivery. FEBS Lett 1995; 357: 140–4
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Bodary S, Garovoy MR. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin Biol Ther 2003; 3: 85–95
   PubMed Web of Science ®Google Scholar
• Dienst A, Grunow A, Unruh M, Rabausch B, Nor JE, Fries JW, Gottstein C. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005; 97: 733–47
   PubMed Web of Science ®Google Scholar
• Driscoll DF. Lipid injectable emulsions: Pharmacopeial and safety issues. Pharm Res 2006; 23: 1959–69
   PubMed Web of Science ®Google Scholar
• Furumoto K, Yokoe JI, Ogawara K, Amano S, Takaguchi M, Higaki K, Kai T, Kimura T. Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm 2007; 329: 110–6
   PubMed Web of Science ®Google Scholar
• Gaitanis A, Staal S. Liposomal doxorubicin and nab-paclitaxel: Nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol 2010; 624: 385–92
   PubMedGoogle Scholar
• Gao J, Zhong W, He JQ, Li HM, Zhang H, Zhou GC, Li BH, Lu Y, Zou H, Kou G, et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int J Pharm 2009; 374: 145–52
   PubMed Web of Science ®Google Scholar
• Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochimica Et Biophysica Acta-Biomembranes 2008; 1778: 854–63
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126–36
   PubMed Web of Science ®Google Scholar
• Jin YC, Kim CW, Kim YM, Nizamutdinova IT, Ha YM, Kim HJ, Seo HG, Son KH, Jeon SJ, Kang SS, et al. Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-α-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. Eur J Pharm 2009; 614: 91–7
   PubMed Web of Science ®Google Scholar
• Kuldo JM, Westra J, Asgeirsdottir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC, Molema G. Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α- and IL-1β-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005; 289: C1229–39
   Web of Science ®Google Scholar
• Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient mice: A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann N Y Acad Sci 1999; 889: 52–61
   PubMed Web of Science ®Google Scholar
• Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13: 1211–20
   PubMed Web of Science ®Google Scholar
• Lim SJ, Kim CK. Homogeneous liposome immunoassay for insulin using phospholipase C from Clostridium perfringens. Anal Biochem 1997; 247: 89–95
   PubMed Web of Science ®Google Scholar
• Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004; 4: 116–23
   PubMed Web of Science ®Google Scholar
• Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999; 40: 89–102
   PubMed Web of Science ®Google Scholar
• Nam K, Kimura T, Kishida A. Preparation and characterization of cross-linked collagen-phospholipid polymer hybrid gels. Biomaterials 2007; 28: 1–8
   PubMed Web of Science ®Google Scholar
• Ries U, Fleer EA, Unger C, Eibl H. Synthetic phospholipids as substrates for phospholipase C from Bacillus cereus. Biochim Biophys Acta 1992; 1125: 166–70
   PubMedGoogle Scholar
• Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003; 4: E33
   PubMedGoogle Scholar
• Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 2008; 5: 189–204
   PubMed Web of Science ®Google Scholar
• Stemme V, Swedenborg J, Claesson H, Hansson GK. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 2000; 20: 146–52
   PubMed Web of Science ®Google Scholar
• Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells – a potential tool for specific drug delivery. Pharm Res 2005; 22: 1906–17
   PubMed Web of Science ®Google Scholar
• Zarghi A, Shafaati A, Foroutan SM, Khoddam A. Simple and rapid high-performance liquid chromatographic method for determination of celecoxib in plasma using UV detection: Application in pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 835: 100–4
   PubMed Web of Science ®Google Scholar
• Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem 2008; 19: 145–52
   PubMed Web of Science ®Google Scholar